Lung disease drug tested in rare muscle condition – trial cut short

NCT ID NCT05335278

Terminated Disease control Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested the drug nintedanib (Ofev) in 11 people with myositis-related interstitial lung disease, a condition where lung scarring occurs alongside muscle inflammation. The goal was to see if the drug is safe and tolerable when added to standard immune-suppressing treatments. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nintedanib (Ofev)
What this could lead to: If successful, this could show that adding nintedanib to standard care is safe and tolerable for people with myositis-related lung disease, potentially slowing disease progression.
What could go wrong: The trial was terminated early with only 11 participants, so results are very limited. It was a small, early-stage safety study, not designed to prove effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antisynthetase syndrome interstitial lung disease myositis disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERSTITIAL LUNG DISEASE MYOPATHY, INFLAMMATORY

Contacts and locations

Locations

Research Institute McGill University Health Center

Montreal, Quebec, H4A3J1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.